Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05760300 · ClinicalTrials.gov registry record · Phase 1

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

A Phase 1 study of Chronic Hepatitis D Infection, sponsored by Gilead Sciences.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target
9
Study locations

NCT05760300 is a Phase 1 study of Chronic Hepatitis D Infection that has completed, run by Gilead Sciences. The registered enrollment target is 41 participants. The trial reports 9 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05760300, a Phase 1 study of Chronic Hepatitis D Infection, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target
9
Study locations

Study Summary

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.

Interventions

  • DRUG Bulevirtide (BLV)

Study Locations (9)

Florida

  • Velocity Clinical Research, New Smyrna Beach - Edgewater
  • Clinical Pharmacology of Miami, LLC - Miami
  • Advanced Pharma CR, LLC - Miami
  • Panax Clinical Research - Miami Lakes
  • Floridian Clinical Research, LLC - Miami Lakes
  • Global Clinical Professionals Research - St. Petersburg
  • Genesis Clinical Research, LLC - Tampa

Massachusetts

  • Massachusetts General Hospital - Renal Associates Clinic - Boston

Minnesota

  • Nucleus Network - Saint Paul

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2023-03-15
Est. Completion 2024-07-23
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

What the Registry Record Tells You About NCT05760300

The ClinicalTrials.gov registry entry for NCT05760300 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Hepatitis D Infection appearing as the primary indexed condition, and to 1 intervention - of which Bulevirtide (BLV) is the first listed.

NCT05760300 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05760300 about?

NCT05760300 is a clinical study titled "A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function". The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with norma...

What is the current status of trial NCT05760300?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-03-15. Estimated completion is 2024-07-23.

What conditions does trial NCT05760300 study?

This clinical trial studies the following conditions: Chronic Hepatitis D Infection.

What interventions are being tested in trial NCT05760300?

The interventions under investigation include: Bulevirtide (BLV) (DRUG).

Who is sponsoring clinical trial NCT05760300?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05760300 being conducted?

This trial has 9 study locations across Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Hepatitis D Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.